Nanobiotix S.A. (NBTX)
Nanobiotix develops nanoparticle medicines, led by a candidate designed to boost the effect of radiotherapy on cancer tumors. It last closed at $27.45 on Nov 17, down 3.82% on the day. NBTX last reported earnings on Tue, Sep 29, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From NBTX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on NBTX in the past 90 days. The average target is $64.00, with a high of $64.00 and a low of $64.00, compared with the last close of $27.45.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 15 | Guggenheim | Assumed coverage | Buy | $64 |
| Jun 4 | Leerink Partners | Maintained | Buy | $46 |
Technical Analysis
The stock is 12% below its 20 day and 9% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the Pivot S1 at $27.18, and the nearest resistance the Pivot at $27.56.
| RSI (14) | 42.17 | Middle of its range | Neutral |
| MACD | 0.24 | Below its signal line | Bearish |
| Stochastic | 19.5 | Near the bottom of its range | Oversold |
| ADX (14) | 18.2 | No clear trend | |
| Williams %R | -98.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -120.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −3.9% | Change over 10 sessions | Bearish |
| ATR (14) | $2.42 | Typical daily range, 8.8% of price |
| RSI (14) | 42.96 | Middle of its range | Neutral |
| MACD | -1.58 | Below its signal line | Bearish |
| Stochastic | 34.2 | Middle of its range | Neutral |
| ADX (14) | 22.7 | Weak trend | |
| Williams %R | -74.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -56.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −25.8% | Change over 10 sessions | Bearish |
| ATR (14) | $5.46 | Typical daily range, 19.9% of price |
What happened before
See how NBTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NBTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in NBTX in the last 90 days.
NBTX Institutional Ownership
Full report →- ▲20 buying vs 9 selling
- ▲Shares held by funds +9.6%
- ▲Funds holding +9
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 28 | 19 | +47.4% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 12 / 8 | 7 / 6 | +53.8% |
| Reduced / sold out | 6 / 3 | 2 / 3 | +80.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBTX is in one of them and how their past NBTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NBTX in an article yet. Here's the latest on the wider market.
About Nanobiotix S.A.
Nanobiotix is a biotechnology company based in Paris, France, that develops medicines built on nanoparticles. Its lead candidate, JNJ-1900 (NBTXR3), is designed to increase the effect of radiotherapy on tumors while limiting the dose to surrounding healthy tissue, and it is in clinical trials for several cancer types, mainly head and neck and lung cancer. The company also works on earlier stage platforms meant to help other drugs reach target tissues and to treat neurological conditions. Its main partner for the lead candidate is Johnson & Johnson, and the medicines are aimed at people receiving cancer treatment.
- Headquarters
- Paris, France

